OBJECTIVES: Phosphoribosylpyrophosphate synthetase (PRPS1) superactivity is an X-linked disorder characterized by urate overproduction Online Mendelian Inheritance in Man (OMIM) gene reference 300661. This condition is thought to rarely affect women, and when it does, the clinical presentation is mild. We describe a 16-year-old African American female who developed progressive tophi, nephrolithiasis and acute kidney failure due to urate overproduction. Family history included a mother with tophaceous gout who developed end-stage kidney disease due to nephrolithiasis and an affected sister with polyarticular gout. The main aim of this study was to describe the clinical manifestations of PRPS1 superactivity in women. METHODS: Whole exome sequencing was performed in affected females and their fathers. RESULTS: Mutational analysis revealed a new c.520 G > A (p.G174R) mutation in the PRPS1 gene. The mutation resulted in decreased PRPS1 inhibition by ADP. CONCLUSION: Clinical findings in previously reported females with PRPS1 superactivity showed a high clinical penetrance of this disorder with a mean serum urate level of 8.5 (4.1) mg/dl [506 (247) μmol/l] and a high prevalence of gout. These findings indicate that all women in families with PRPS1 superactivity should be genetically screened for a mutation (for clinical management and genetic counselling). In addition, women with tophaceous gout, gout presenting in childhood, or a strong family history of severe gout should be considered for PRPS1 mutational analysis.

Institute of Inherited Metabolic Disorders 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Pediatric Rheumatology Children's Hospital at Montefiore Bronx NY USA

Pediatric Rheumatology Nicklaus Children's Hospital Miami FL USA

Section on Nephrology Wake Forest School of Medicine Winston Salem NC

Zobrazit více v PubMed

Porrmann J, Betcheva-Krajcir E, Di DN. et al. Novel PRPS1 gain-of-function mutation in a patient with congenital hyperuricemia and facial anomalies. Am J Med Genet A 2017;173:2736–42. PubMed

Simmonds HA, Webster DR, Wilson J, Lingham S.. An X-linked syndrome characterised by hyperuricaemia, deafness, and neurodevelopmental abnormalities. Lancet 1982;2:68–70. PubMed

Becker MA, Raivio KO, Bakay B, Adams WB, Nyhan WL.. Superactive phosphoribosylpyrophosphate synthetase with altered regulatory and catalytic properties. Adv Exp Med Biol 1980;122A:387–92. PubMed

Nyhan WL, James JA, Teberg AJ, Sweetman L, Nelson LG.. A new disorder of purine metabolism with behavioral manifestations. J Pediatr 1969;74:20–7. PubMed

Becker MA, Meyer LJ, Wood AW, Seegmiller JE.. Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science 1973;179:1123–6. PubMed

Becker MA, Losman MJ, Itkin P, Simkin PA.. Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med 1982;99:495–511. PubMed

García-Pavía P, Torres RJ, Rivero M. et al. Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum 2003;48:2036–41. PubMed

Sperling O, Boer P, Brosh S, Zoref E, De VA.. Superactivity of phosphoribosylpyrophosphate synthetase, due to feedback resistance, causing purine overproduction and gout. Ciba Found Symp 1977;48:143–64. PubMed

Takeuchi F, Hanaoka F, Yano E. et al. The mode of genetic transmission of gouty family with increased phosphoribosylpyrophosphate synthetase activity. Hum Genet 1981;58:322–30. PubMed

Hartmannova H, Piherova L, Tauchmannova K. et al. Acadian variant of Fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a non-coding mutation in complex I assembly factor NDUFAF6. Hum Mol Genet 2016;25:4062–79. PubMed

Musalkova D, Minks J, Storkanova G, Dvorakova L, Hrebicek M.. Identification of novel informative loci for DNA-based X-inactivation analysis. Blood Cells Mol Dis 2015;54:210–6. PubMed

Kmoch S, Hartmannová H, Stribůrková B. et al. Human adenylosuccinate lyase (ADSL), cloning and characterization of full-length cDNA and its isoform, gene structure and molecular basis for ADSL deficiency in six patients. Hum Mol Genet 2000;9:1501–13. PubMed

Zikanova M, Skopova V, Hnizda A, Krijt J, Kmoch S.. Biochemical and structural analysis of 14 mutant adsl enzyme complexes and correlation to phenotypic heterogeneity of adenylosuccinate lyase deficiency. Hum Mutat 2010;31:445–55. PubMed

Li S, Lu Y, Peng B, Ding J.. Crystal structure of human phosphoribosylpyrophosphate synthetase 1 reveals a novel allosteric site. Biochem J 2007;401:39–47. PubMed PMC

Li B, Li H, Bai Y. et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med 2015;21:563–71. PubMed PMC

de Brouwer AP, van BH, Nabuurs SB. et al. PRPS1 mutations: four distinct syndromes and potential treatment. Am J Hum Genet 2010;86:506–18. PubMed PMC

Bleyer AJ, Kidd K, Živná M, Kmoch S.. Autosomal dominant tubulointerstitial kidney disease. Adv Chronic Kidney Dis 2017;24:86–93. PubMed PMC

Zivná M, Hůlkova H, Marignon M. et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Human Genet 2009;85:204–13. PubMed PMC

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients